Aytu Biopharma (AYTU) Cash from Financing Activities (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Cash from Financing Activities data on file, last reported at $872000.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $872000.0, down 79.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 million (up 181.35% YoY), and the FY2025 annual result was $15.4 million, up 1323.69% from the prior year.
• Cash from Financing Activities grew to $872000.0 in Q1 2026 per AYTU's latest filing, from -$6.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $13.6 million in Q3 2022 and troughed at -$6.3 million in Q4 2025.
• A 5-year average of $1.2 million and a median of $872000.0 in 2026 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 2090.48% in 2024, then surged 1116.57% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.9 million in 2022, then soared by 93.24% to -$126000.0 in 2023, then sank by 2090.48% to -$2.8 million in 2024, then plunged by 126.92% to -$6.3 million in 2025, then surged by 113.92% to $872000.0 in 2026.
• Business Quant data shows AYTU's Cash from Financing Activities at $872000.0 in Q1 2026, -$6.3 million in Q4 2025, and $2.3 million in Q3 2025.